Fundz Deep Dive
Everything you need to win Ailux Biologics a Division of XtalPi — in one platform.
Who to reach, what to say, and why now on Ailux Biologics a Division of XtalPi — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Ailux Biologics a Division of XtalPi — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Contract Type
agreement
CambridgeBiotechnologyArtificial IntelligenceTherapeuticsPharmaceuticalDescription
Ailux Biologics, a division of XtalPi, has entered into a license agreement with Janssen Biotech, a Johnson & Johnson company. The agreement grants Janssen and its affiliates a non-exclusive license to leverage Ailux Biologics' XtalFold™ platform for the discovery and engineering of biologics.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months